In this study, we aimed to assess the clinicopathologic features, natural history, and outcomes of ER-/PgR+ breast carcinomas and compared these to ER+ and ER-/PgR- tumors, using a retrospectively collected individual patient dataset. This evidence concerns the gene PGR and breast carcinoma.